hVIVO
Update in progressHVO.L (LSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
hVIVO plc is a UK-based pharmaceutical services and contract research company serving Europe, North America, and beyond. It conducts human challenge trials for vaccines and antivirals and provides extensive laboratory services, including assay development, virology, immunology, and biomarker analysis, plus clinical logistics and data management. Its model portfolio covers RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD. Formerly Open Orphan, it rebranded in Oct 2022 and is headquartered in London.
Company score
- Sentiment
- 0.41
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.18
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!